Cellares and City of Hope signed a collaboration to evaluate automated, high‑throughput manufacturing and QC for a CAR‑T program targeting glioblastoma multiforme. City of Hope will test Cellares’ Cell Shuttle and Cell Q automation platforms on its investigational IL13RA2‑EGFR CAR T program (CARpool) to establish scalable manufacturing processes. The deal aims to standardize production and analytics at the preclinical stage to reduce failure rates and enable reproducible scale‑up for solid‑tumor CAR‑T therapies, which face unique manufacturing and tumor‑microenvironment challenges. City of Hope emphasized the need for rigorous translational science plus reproducible manufacturing to improve clinical translation in glioblastoma. Cellares said early integration of automation should lower costs, shorten timelines and expand patient access if clinical translation and regulatory validation succeed.